Celgene Corporation (CELG) : Bourne Lent Asset Management Inc scooped up 740 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 455,147 shares of Celgene Corporation which is valued at $45,628,487.Celgene Corporation makes up approximately 36.74% of Bourne Lent Asset Management Inc’s portfolio.
Celgene Corporation closed down -1.46 points or -1.44% at $100.25 with 37,28,230 shares getting traded on Friday. Post opening the session at $100.72, the shares hit an intraday low of $99.27 and an intraday high of $102.11 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Tributary Capital Management reduced its stake in CELG by selling 1,200 shares or 15.0% in the most recent quarter. The Hedge Fund company now holds 6,800 shares of CELG which is valued at $681,700. Celgene Corporation makes up approx 0.11% of Tributary Capital Management’s portfolio.Wealthtrust Axiom boosted its stake in CELG in the latest quarter, The investment management firm added 150 additional shares and now holds a total of 2,150 shares of Celgene Corporation which is valued at $222,332. Celgene Corporation makes up approx 0.09% of Wealthtrust Axiom’s portfolio.Candriam Luxembourg S.c.a. reduced its stake in CELG by selling 78,061 shares or 11.85% in the most recent quarter. The Hedge Fund company now holds 580,639 shares of CELG which is valued at $60,043,879. Celgene Corporation makes up approx 1.50% of Candriam Luxembourg S.c.a.’s portfolio.Umb Bank N Amo reduced its stake in CELG by selling 2,897 shares or 13.82% in the most recent quarter. The Hedge Fund company now holds 18,067 shares of CELG which is valued at $1,996,765. Celgene Corporation makes up approx 0.08% of Umb Bank N Amo’s portfolio.Atria Investments boosted its stake in CELG in the latest quarter, The investment management firm added 1,155 additional shares and now holds a total of 12,729 shares of Celgene Corporation which is valued at $1,406,809. Celgene Corporation makes up approx 0.16% of Atria Investments’s portfolio.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .Citigroup Initiated Celgene Corporation on Feb 25, 2016 to “Buy”, Price Target of the shares are set at $130.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.